Plain-English translation of NCT07567235 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing whether a new treatment called CFH protein, delivered through special ice microneedles applied to the skin, can prevent radiation-induced skin fibrosis (thickening and scarring of the skin). The study will enroll 9 patients with head and neck cancer who are about to undergo radiation therapy after surgery. Researchers want to learn whether this treatment is safe, well-tolerated, and potentially effective at reducing the scarring that commonly develops after radiation.
Radiation therapy for head and neck cancer often causes lasting skin damage—thickening, hardening, and scarring that can be uncomfortable and affect quality of life. There is currently no proven preventive treatment, so this trial is exploring whether this medication can protect the skin and reduce this common side effect.
You likely qualify if…
You likely don't qualify if…
Participants will receive the medication twice a week for a total of 8 doses, starting on the first day of their radiation therapy. The treatment involves applying a special ice microneedle patch to the skin area that will receive radiation—this is a non-invasive procedure that delivers the protein into the skin. Participants will be monitored for side effects within the first 28 days and beyond, and their skin will be assessed over time to measure whether scarring is reduced. The study is designed to test three different dose levels, starting with the lowest dose and increasing only if earlier doses prove safe.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China